Rocket Pharmaceuticals (RCKT) Prices 4.64M Share Upsized Common Offering at $56/Sh

Pre-Open Stock Movers 12/09: (MTSC) (RCKT) (QS) Higher; (PSTI) (PLAB) (GME) Lower (more...)

Today's Pre-Open Stock Movers:

MTS Systems Corporation (Nasdaq: MTSC) 49% HIGHER; Amphenol Corporation (NYSE: APH) (Amphenol), a leading global provider of high-technology interconnect, antenna and sensor solutions,... More

Rocket Pharmaceuticals (RCKT) Announces $175M Proposed Public Offering of Common Stock

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that it has commenced an underwritten public offering of $175 million of shares of its common stock. Rocket also intends to grant the underwriters a... More

Rocket Pharmaceuticals (RCKT) PT Raised to $60 at Piper Sandler After Positive POC Data

Piper Sandler analyst Tyler Van Buren raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $60.00 (from $50.00) after the initial clinical update from Rocket's RP-A501 Danon program. While early, but in the two low dose patients with adequate immunosuppresion, LAMP2B expression... More

After-Hours Stock Movers 12/08: (RCKT) (PRPH) (SDC) Higher; (GME) (DCTH) (TALO) Lower (more...)

Today's After-Hours Stock Movers:

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) 33.4% HIGHER; announces preliminary data from its open-label, Phase 1 clinical trial of RP-A501, the Companys adeno-associated viral vector (AAV)-based gene therapy candidate expressing LAMP2B for the treatment of Danon Disease. Danon Disease is a rare X-linked inherited disorder caused by genetic mutations in the LAMP2 gene resulting in accumulation of autophagosomes and glycogen, particularly in cardiac muscle and other tissues, which ultimately leads to severe and frequently fatal cardiomyopathy. Preliminary data from patients in the low dose... More

Rocket Pharmaceuticals (RCKT) Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for Treatment of Danon Disease

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces preliminary data from its open-label, Phase 1 clinical trial of RP-A501, the Companys adeno-associated viral vector (AAV)-based gene therapy candidate expressing LAMP2B for the treatment of... More

UPDATE: Oppenheimer Downgrades Rocket Pharmaceuticals (RCKT) to Perform

(Updated - December 8, 2020 6:05 AM EST)

(updating comment)

Oppenheimer analyst Kevin DeGeeter downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Outperform to Perform.

The analyst comments "While we view yesterday's FA update as supportive of a path toward regulatory approval,... More